US Court Rules Against Merck in NASONEX Lawsuit; GSK Receives FDA Approval for MenHibrix Print E-mail
By Staff and Wire Reports   
Friday, 15 June 2012 18:23
Below is a look at some of the headlines for companies that made news in the healthcare sector on June 15, 2012.

Merck (NYSE: MRK) announced the U.S. District Court for the District of New Jersey ruled against the company in a patent infringement suit against Apotex Inc. and Apotex Corp.

"While we are pleased with the court's ruling that the patent for NASONEX is valid, we are disappointed the court ruled that this patent would not be infringed by the Apotex product. We believe the patent for NASONEX in the United States is valid and would be infringed by the Apotex product," said Bruce N. Kuhlik, executive vice president and general counsel of Merck. "Today's decision reflects just one step in the lengthy patent litigation process, and we plan to review all of our options, including a likely appeal of the decision."

The patent at issue in this case is U.S. Patent No. 6,127,353 that covers mometasone furoate monohydrate, the active ingredient in NASONEX and which provides exclusivity for this form of mometasone until April 3, 2018.

Apotex is seeking U.S. Food and Drug Administration approval to sell a generic version of NASONEX.


GlaxoSmithKline plc (NYSE: GSK)
announced the U.S. FDA has approved the vaccine MenHibrix® [Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine].

MenHibrix is a vaccine indicated to prevent invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b. MenHibrix is approved for use in children aged six weeks through 18 months.

Also Friday:

Aperture Health, Inc. (OTC APRE)
is intending to capitalize on the strength of management's experience in the coordination of care at home and  the direct provision of hi-tech disease specific pharmacy services in the alternate care setting.

BioMed Realty Trust, Inc. (NYSE: BMR)
today announced that its board of directors has declared a second quarter 2012 dividend of $0.215 per share of common stock.  The dividend is equivalent to an annualized dividend of $0.86 per common share.

DARA BioSciences, Inc. (Nasdaq: DARA)
announced today that Dr. David J. Drutz, Chief Executive Officer, will provide a comprehensive update on the company’s products and pipeline at the 2012 BIO International Convention in Boston later this month.

, the leader in continuous glucose monitoring, is proudly sponsoring the efforts of the Diabetes Formation Flight USA ( -- three pilots with insulin-dependent diabetes using DexCom's Seven Plus as part of their effort to set new transcontinental world speed records while raising funds for the Juvenile Diabetes Research Foundation (JDRF).

Human Genome Sciences, Inc. (Nasdaq: HGSI)
today announced that, in connection with its ongoing strategic alternative review process, it had previously set a bid date of July 16, 2012 for the submission of definitive proposals to acquire all outstanding common shares of HGS.

Idera Pharmaceuticals, (NASDAQ: IDRA)
a biotechnology company developing novel therapeutics for autoimmune diseases and vaccine adjuvants, today announced that members of the management team will be presenting at the 2012 BIO International Convention at the Boston Convention and Exhibition Center in Boston, MA.

Life Technologies Corporation (NASDAQ: LIFE)
today announced that it has deepened its commitment to stem cell research and its customers by signing a  non-exclusive agreement with iPS Academia Japan for its induced pluripotent stem (iPS) cell patent portfolio.

MDxHealth SA (NYSE Euronext: MDXH)
, a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, held its Extraordinary General Meeting of shareholders in Zaventem today.

MMRGlobal, Inc. (OTCBB: MMRF)
("MMR") today announced that usage of the Company's MMRPro document management and imaging systems processed nearly 3 million pages of medical records from an estimated 100,000 patients including more than 500,000 EOB forms for use with medical billing and collection services.

Oncolytics Biotech Inc. (TSX: ONC) (NASDAQ: ONCY)
announced today that its 2012 Annual and Special Meeting of Shareholders will be held on Wednesday, June 20, 2012 at 4:30 p.m. ET at the Hilton Toronto Hotel, 145 Richmond Street West, Toronto, Ontario.

Ohr Pharmaceutical Inc. (OTCBB: OHRP) announced today that Michael J. Elman, M.D., a member of Ohr Pharmaceutical's scientific advisory board, will be giving a presentation on the Squalamine Eye Drop program on Friday, June 15 at the Macula Society annual meeting taking place in Jerusalem, Israel from June 11-15, 2012., Inc. (PINKSHEETS: SEEK)
, an emerging leader in the vertical and Local search space, today announced that it has launched the world's first Chiropractic search engine

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus